Ipsen in France
Development and manufacturing
Ipsen’s research, development, registration, production and storage of oral drugs is carried out at Dreux. The manufacturing site specializes in the production of oral formulations. In 2013, the site manufactured over 1.1 billion sachets, 621 million tablets and capsules and 1.4 million vials. Work at the facility is carried out on chemical and biological compounds, including the nature and substance of drugs, manufacturing processes and manufacturing control methods. The Dreux site also mutualizes the distribution for most of the group’s products.
L’Isle-sur-la-Sorgue has been Ipsen’s only site for processing clays since 1963. The facility processes over 8,000 tons of raw materials each year and produces more than 3,500 tons of finished products. Approximately two-thirds of the production is for Europe and China. The site has been GMP and ISO 14001 certified since 2004.
The R&D center was created in 1939. One of the site’s main missions is to advance knowledge of the molecular, pharmacodynamic and pharmacokinetic properties of new chemical or biological entities as candidates for development in the fields of oncology and neurology. Les Ulis also houses a significant clinical development activity.
The Signes facility was created in 1990 for the manufacturing of products intended for export. It specializes in the manufacturing of injectable formulations, particularly sustained-release formulations of peptides (Decapeptyl®, Somatuline®, and Nutropin Aq®). Signes produces close to 50% of the Group’s drug sales (approximately 2.9 million boxes per year) and exports to more than 70 countries.
27 September 2016 - Paris (France)
Ipsen announces data presentations of cabozantinib (Cabometyx™), lanreotide (Somatuline® Autogel®) and telotristat ethyl* at the…